{"id":"NCT03183141","sponsor":"Seres Therapeutics, Inc.","briefTitle":"ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection","officialTitle":"ECOSPOR IV: An Open-Label Extension of Study SERES-012 and Open-Label Program for Evaluating SER-109 in Subjects With Recurrent Clostridioides Difficile Infection (RCDI)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-23","primaryCompletion":"2022-04-29","completion":"2022-04-29","firstPosted":"2017-06-09","resultsPosted":"2023-03-31","lastUpdate":"2023-04-10"},"enrollment":263,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Clostridioides Difficile Infection"],"interventions":[{"type":"BIOLOGICAL","name":"SER-109","otherNames":["Firmicutes spores"]}],"arms":[{"label":"SER-109","type":"EXPERIMENTAL"}],"summary":"Cohort 1: Subjects who had a Clostridioides difficile infection (CDI) recurrence in study SERES-012 within 8 weeks of receipt of study drug will be eligible. The purpose of this cohort is to assess safety and efficacy of SER-109 in reducing recurrence of CDI in adults who had a CDI recurrence within 8 weeks after receipt of SER-109 or Placebo in study SERES-012.\n\nCohort 2: Cohort 2 is an open-label program for subjects who were not part of SERES-012. The purpose of this cohort is to describe safety and tolerability of SER-109 in subjects 18 years of age or older with at least a first recurrence of CDI.","primaryOutcome":{"measure":"Cohort 1: Recurrence of CDI and Sustained Clinical Response","timeFrame":"Up to Week 8","effectByArm":[{"arm":"Cohort 1","deltaMin":4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":107,"countries":["United States","Canada"]},"refs":{"pmids":["38941068","36780159"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":29},"commonTop":["Diarrhea","Flatulence","Nausea","Abdominal pain"]}}